BLOOMFIELD, N.J., Dec. 6 /PRNewswire-FirstCall/ -- Alfacell Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease (RNase) therapeutics for cancer and other life-threatening diseases, today announced that its Annual Shareholder Meeting will be held on Thursday, January 19, 2006 at 2:00PM EST in Somerset, NJ at the Somerset Marriott.
The agenda is expected to include the election of the Company’s new Board of Directors; updates from the management team on the ONCONASE(R) (ranpirnase) confirmatory Phase IIIb trial and ongoing preclinical and clinical programs, a review of other business activities, and a look forward to key milestones in 2006. For more information, please visit the Company’s website at www.alfacell.com to view a copy of the Annual Letter to Shareholders from Kuslima Shogen, Chairman and CEO of Alfacell.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary RNase technology platform. ONCONASE(R) (ranpirnase), Alfacell’s lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for unresectable malignant mesothelioma (UMM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company’s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.comacel@efcg.net
Alfacell Corporation
CONTACT: Kuslima Shogen or Robert Love, both of Alfacell Corporation,+1-973-748-8082, info@alfacell.com; or Investors, Dodi Handy of EliteFinancial Communications, +1-407-585-1080, acel@efcg.net, for AlfacellCorporation
Web site: http://www.alfacell.com/